報價延遲最少15分鐘:2025/08/25 16:58 EDT
盤後時段
|
||||
|
1.83 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.83
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.06/-0.39
|
|
企業價值
111.25M
|
| 資產負債 |
|
每股賬面淨值
0.23
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
69.30M
|
|
每股收益
1.24
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/25 16:58 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. |
